Program Signaling and Experimental Therapeutics

程序信号传导和实验治疗

基本信息

批准号：
8340072
负责人：
George J. Weiner
金额：
$ 4.9万
依托单位：
UNIVERSITY OF IOWA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-19 至 2016-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8340072
关键词：
Androgens Antineoplastic Agents Area Basic Science Cancer Biology Cancer Center Cancer Center Support Grant Cancer Immunology Science Cancer Patient Cell Adhesion Cell Proliferation Cell Survival Cells Cessation of life Chemicals Clinical Clinical Trials Collaborations Computational Biology Conduct Clinical Trials Coupled Development Drug Delivery Systems Endometrial Carcinoma Erinaceidae Estrogen Receptors Estrogens Faculty Funding GTP-Binding Proteins Goals Grant Guanosine Triphosphate Phosphohydrolases Hormonal Immune response Individual Instruction Integrins Knowledge Link Malignant Neoplasms Malignant neoplasm of prostate Modality Monomeric GTP-Binding Proteins NF-kappa B Neoplasm Metastasis Paper Pathway interactions Pharmaceutical Preparations Pharmacotherapy Phenotype Phosphotransferases Progesterone Protein Kinase Publications Publishing RNA RNA Interference Receptor Signaling Research Research Activity Research Peer Review Research Personnel Role Signal Pathway Signal Transduction Signaling Molecule Signaling Protein Testing Therapeutic Therapeutic Human Experimentation Translating Tumor Biology United States National Institutes of Health Universities Vascular Endothelial Growth Factor Receptor anti-cancer therapeutic aptamer base cancer cell cancer epidemiology cancer genetics cancer immunotherapy cancer therapy college design high throughput screening immune RNA improved innovation interest isoprenoid malignant breast neoplasm member new therapeutic target next generation novel novel strategies novel therapeutic intervention novel therapeutics pre-clinical programs receptor response small molecule success tumor tumor progression validation studies

项目摘要

PROJECT SUMMARY (See instructions): Cancer Signaling and Experimental Therapeutics Research in the Cancer Signaling and Experimental Therapeutics (CSET) Program focuses cell signaling pathways and how they impact cancer progression and therapy. The overall goal of the members of this program is to elucidate basic signaling mechanisms relevant to tumor biology and apply this knowledge to the discovery and development of new therapeutic approaches. There are two major overiapping themes within the Program's research: The first theme is Cancer Signaling and is comprised of three interrelated research areas; GTPases and kinases, hormonal signaling and cell adhesion signaling. The second theme is Experimental Therapeutics and is comprised of three interrelated research areas; drug delivery and RNA interference, small molecules and clinical trials. Major accomplishments of the Cancer Signaling and Experimental Therapeutics Program over the past funding period include identification of a new therapeutic target in estrogen receptor signaling in breast cancer, advancement of novel isoprenoid anti-cancer compounds into pre-clinical validation studies, and development of RNA-aptamer-based systemic delivery of RNA-interference in prostate cancer. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. For example, within the program Co-leader Dr. Hohl and Dr. Wiemer have collaborated to develop novel isoprenoid compounds with anti-cancer activity and advance these toward clinical trials and Program Leader Dr. Henry shares separate NCI and NIH grant funding with Drs. Quelle and Lynch, Leaders of the Cancer Genetics and Computational Biology and Cancer Epidemiology programs, respectively and has published recently with Dr. Ballas Leader of the Cancer Immunology and Immunotherapy program. The program consists of 45 members from 7 basic science and 8 clinical departments and 3 Colleges. Peer-reviewed, research funding for this program totals $9.8 million with $3.5 million coming from the NCI. Program members published 339 cancer related papers over the prior funding period. Of these publications, 8% were intraprogrammatic, 27% were interprogrammatic and 2% were both intra and interprogrammatic, for a total of 37% collaborative publications.

项目摘要（参见说明）：癌症信号传导和实验治疗癌症信号转导和实验治疗 (CSET) 计划的研究重点是细胞信号转导通路及其如何影响癌症进展和治疗。该计划成员的总体目标是阐明与肿瘤生物学相关的基本信号传导机制，并将这些知识应用于新治疗方法的发现和开发。该计划的研究有两个主要的重叠主题：第一个主题是癌症信号转导，由三个相互关联的研究领域组成； GTPa 酶和激酶、激素信号传导和细胞粘附信号传导。第二个主题是实验治疗学，由三个相互关联的研究领域组成；药物输送和 RNA 干扰、小分子和临床试验。癌症信号传导和实验治疗计划在过去资助期间的主要成就包括确定乳腺癌雌激素受体信号传导的新治疗靶点、将新型类异戊二烯抗癌化合物推进临床前验证研究以及开发RNA-前列腺癌中基于适配子的 RNA 干扰系统递送。该计划的成员之间以及与其他癌症中心计划的成员之间过去和现在都有许多富有成效的合作。例如，在该项目联合负责人 Hohl 博士和 Wiemer 博士合作开发了具有抗癌活性的新型类异戊二烯化合物，并将其推进临床试验，项目负责人 Henry 博士与 Dr. Hohl 和 NIH 博士分享单独的 NCI 和 NIH 拨款资金。 Quelle 和 Lynch 分别是癌症遗传学和计算生物学以及癌症流行病学项目的负责人，最近与 Dr. Quelle 一起发表了论文。 Ballas 癌症免疫学和免疫治疗项目的负责人。该项目由来自7个基础科学和8个临床部门以及3个学院的45名成员组成。经过同行评审，该项目的研究经费总计 980 万美元，其中 350 万美元来自 NCI。计划成员发表了 339 篇与癌症相关的文章先前资助期间的论文。在这些出版物中，8% 是计划内出版物，27% 是计划间出版物，2% 是计划内出版物和计划间出版物，总共 37% 是合作出版物。